PhysiologicalTherapyin chronic and recurrent infections

The Homeopathic Use of Transfer factors

GGUUNNAA--TTFFGUNA-TF

By Guna® S.p.a. Scientific Department

© Copyright 2006 Guna® S.p.a.

GUNA-TF are Transfer Factors protein-based innovative homeopathic

medicines at D7 (7 X for US Physicians) potency (10-7).

The Transfer Factors are therapeutically active at a dosage of 100

ng/day; to obtain this specific concentration (corresponding to the

amount of Transfer Factors that are contained in a Guna-TF capsule),

the technique of homeopathic preparation has been used in order to

realize a standard production according to current Good

Manufacturing Practice.

Transfer factors are short ribonucleopeptide chains with antigenic

messenger RNA bases connected with short peptide chains

composed of 6 or more amino acids. In simple words, they are tiny

molecules providing for immune defence. They are all natural

substances that work by “teaching” our own immune system to

identify infectious agents that attack our body every day.

Guna-TF are manufactured through a patented procedure by

extracting them from lymph cells activated by specific antigens

(viruses, yeasts, etc.).

These Lymphoid lines are being cultivated in vitro and dialysed: in

this way, the so-called DLE (Dialyzable Leukocyte Extract) can be

containing over 200 molecules, weighting between 1.000 and

20.000 Dalton. Among these, there are Transfer Factors proteins

responsible for the transfer of cell-mediated immunity.

GGUUNNAA--TTFF??WHAT ARE GUNA-TF?

GUNA-TF

One of the most common theories on the mechanism of action of

Transfer Factors is that they are part of the receptor lying on the Th

lymphocyte surface in a steric position that is necessary to identify

the specific antigenic agent.

Administering Transfer Factors proteins means activating the

mechanisms of receptor re-synthesization (specific receptors of a

specific antigen) by Th lymphocytes, thus enhancing their receptor

capacity and hence their immune effectiveness.

Transfer Factors are also capable of activating intracell

mechanisms responsible for the production of cytokines, which are

important intracell communication messengers between different

immune response intermediates. In particular, they activate the

synthesis of pro-inflammatory interleukins (for instance IL1, IL6,

TNF, INF, etc) which are essential to induce an effective

physiological response towards a pathogen agent.

GUNA-TF

GGUUNNAA--TTFF GUNA-TF MECHANISM OF ACTION

COMPLEMENT FACTORS

GUNA-TF

The chronicization and recurrence of an infectious disease represent

the most evident sign that the Immune System has been attacked by

pathogen agents.

Transfer Factors struggle against the body non-response by providing it

with the necessary factors to help the Immune System face the antigen

attack.

Guna-TF treatment is capable of transferring the immune pathway of

the donor of Transfer Factors to the patient to be treated to trigger an

autologous response that has to be sufficient and suitable to fight the

antigenic attack in a physiological way.

The treatment with Guna-TF is suitable in the forms of cell-mediated

immune selected deficit.

The response is specific only toward the antigen codifying the Transfer

Factor:

• Herpes simplex type 1 and 2 ·Guna-TF Herpes• Monilia albicans ·Guna-TF Candida• HPV ·Guna-TF Papilloma

GGUUNNAA--TTFF FOR WHICH DISEASES CANGUNA-TF BE USED?

á100 ng/die = quantity of Transfer Factors proteins that are therapeutically active and correspond to the quantity of TF D7 (7 X for US Physicians) in a capsule of Guna-TF

áTransfactor = Transfer of cell-mediated immunity

áTransfactor = Antigen-specific immunotherapy

á

á Transfactor = Physiological treatment of chronic recurrent infections diseases

á Transfactor = Effective and risk-free treatment

HOW TO USE GUNA-TF:

• Guna-TF are in capsules for oral use.

• Standard dosage: 1 capsule/day for 5 continuous days (for

instance: from Monday to Friday, excluding Saturday and Sunday)

for 3-4 months without break.

PACKAGE SIZE

Bottle of 20 x 230 mg capsules.

GGUUNNAA--TTFFGUNA-TF

Tran

sfac

tor:

Key

note

s

GGUUNNAA--TTFF HHEERRPPEESSGUNA-TF HERPES

GUNA-TF HERPES

Composition Transfer Factors-HSV

type 1 and 2 at D7 potency

(7X for US Physicians).

Indications Herpes labialis and Herpes genitalis

recurrent infections; herpetic

keratoconjunctivitis; herpetic-like

cutaneous infections.

Dosage 1 capsule/day for 5 continuous days (for instance:

from Monday to Friday, excluding Saturday and Sunday)

for 3-4 months without break.

Package size Bottle of 20 x 230 mg capsules.

Combination with other Guna medicines:

· Strengthening of immune defenses in Herpes simplex I and II infections:

Guna-TF Herpes + Guna-Virus

A clinical research study has been carried out on 44 patients, 22 affected by labial herpes and 22affected by genital herpes.All the patients have been treated for 6 continuous months with a Transfer Factor preparationobtained from in vitro culture extract of specific HSV 1 and 2 from dyalized bovine lymphocytes.

In the monitoring period before the treatment (the 44 patients have been monitored globally 26.660days long) there have been 544 reacutizations with a 61.2 Relapse Index.

The monitoring period during and after treatment has been of 16.945 days for the 44 patients. Inthis period there have been 121 reacutizations with a 21.4 Relapse Index.

From Pizza G, Viza V, De Vinci C, Palareti AP, Cuzzocrea DE, Fornarola V & Baricordi OR. “Orally administered HSV-specific

transfer factor (TF) prevents genital and/or labial herpes relapses”. Biotherapy, Vol. 9:62-72, 1996.

Prevention of recurrent labial and genital herpes infections

Clinical case

Composition Transfer Factor Monilia albicans

at D7 potency

(7X for US Physicians).

Indications Recurrent Candida infections;

mucocutaneous yeast problems

in different body areas; dermatitis.

Dosage 1 capsule/day for 5 continuous days

(for instance from Monday to Friday,

excluding Saturday and Sunday) for 3-4 months without break.

Package size Bottle of 20 x 230 mg capsules.

Combination with other Guna medicines:

· Acute and chronic Vulvo-vaginites as a consequence of yeast problems

(Candidiasis):

Guna-TF Candida + MycoxTM + CitomixTM (20 drops three times/day for 1 month)

· Dysbiotic Candidiasis: Guna-TF Candida + EubioflorTM+ CitomixTM

(20 drops three times/day for 2 months)

GGUUNNAA--TTFF CCAANNDDIIDDAAGUNA-TF CANDIDA

GUNA-TF CANDIDA

Guna-TF-Candida in chronic mucocutaneous Candidiasis

Clinical case

A clinical research study has been carried out on 15 patients (3 M; 12 F) affected by ChronicMucocutaneous Candidiasis (6 patients with oral Candidiasis and 9 patients with VaginalCandidiasis).The patients have been treated with a Transfer Factor preparation from in vitro culture extract ofMonilia albicans. The CMI (Cell-Mediated Immunity) has been considered through the LeukocyteMigration Test (LMT) and the Lymphocyte Stimulation Test (LST) with the presence of Candidiasis lysatebefore, during and after treatment.83.9% of LMTS Test were positive during treatment, showing an increased incidence of Candidiasisantigen reactivity.In the monitoring period improvements of the health condition have been recorded.

From Masi M., De Vinci C., Baricordi O.R. “Transfer Factor in chronic mucocutaneous candidiasis”. Biotherapy. 9(1-3)97-103, 1996.

GGUUNNAA--TTFF PPAAPPIILLLLOOMMAAGUNA-TF PAPILLOMA

GUNA-TF PAPILLOMA

Composition Transfer Factor Papillomavirus

at D7(7 X for US Physicians) potency.

Indications Recurrent Papillomavirus infections;

condylomatoses; post-surgical

condyloma treatment; warts.

Dosage 1 capsule/day for 5 continous days

(for instance from Monday to Friday,

excluding Saturday and Sunday) for 3-4 months without break.

Package size Bottle of 20 x 230 mg capsules.

Combination with other Guna medicines:

· Strengthening of immune defenses in Human Papilloma Virus (HPV)

infections: Guna-TF Papilloma + CitomixTM

A clinical research study has been carried out on 160 patients, both male and female, affected byHPV (Papilomavirus) lesions or PAP test or biopsy positive to koilocytosis to consider the results of atreatment with Transfer Factor preparation from in vitro culture HPV extract to prevent relapses.The protocol provided for the use of one capsule/day for 5 continuous days/week for 8 weeks andthen one capsule/day for 3 days/week (on alternate days) for another 4 weeks.The viral HPV lesions have almost disappeared in the patients treated.In 97% of the cases where the electrosurgical treatment has been used in conjunction with thepreparation no further persistent symptoms of disease have been recorded.

From M. Destro Castaniti. “L'utilizzo del Transfactor 11 nella patologia virale da HPV (casistica di 160 casi)”. La Medicina

Biologica, 2000/4; 95-100.

Use of TF-Papilloma in HPV disease

Clinical case

1. Blume M.R., Rosenbaum E.H., Cohen R.J.,

Gerhow J, Glassberg AB, Shepley E. -

Adjuvant immunotherapy of high risk stage

I melanoma with transfer factor. Cancer,

47, 882-888, 1981.

2. Borden E.C. - Augmented tumour-associa-

ted antigen expression by interferons. JNCI,

80, 148-149, 1988.

3. Bukowski R.M., Deodhar S., Hewlett J.S.,

Greenstreet R. - Randomized controlled trial

of transfer factor in stage II malignant mela-

noma. Cancer 51, 269-272, 1983.

4. Conti F., Orlandini A. - Trattamento di mani-

festazioni allergiche con Transfer Factor

(TF). La Medicina Biologica, 1998/3; pp.

35-39.

5. Corrado F., Pizza G., De Vinci C., Corra-

do G., Mannini D., Maver P., Ferri C., Aiel-

lo E. - L'impiego del transfer factor nel car-

cinoma prostatico metastatizzato. In Atti del

Convegno Internazionale sul Cancro della

Prostata. Garofalo F, Tomaselli V Eds. Mon-

duzzi Editore, Bologna. p. 89-92, 1988.

6. Corrado F., Pizza G., De Vinci C., Corra-

do G. - Il trattamento con transfer factor del-

le metastasi ossee da adenocarcinoma del-

la prostata. In: Le Metastasi, Atti XII Cong

Naz Oncol, Saccani F, Becchi G, Carretti

D, Maltoni C Ed, Monduzzi Editore, Bolo-

gna, 1233-1235, 1986.

7. Corrado F., Pizza G. - Tentativas de inmu-

noterapia en los tumores del aparato urina-

rio. Arch Esp Urol, 37, 659-666, 1984.

8. Destro Castaniti M. - L'utilizzo del Transfac-

tor 11 nella patologia virale da HPV (casi-

stica di 160 casi) - La Medicina Biologica

2000/4, pagg. 95-100.

9. Fudenberg H.H., Fudenberg H.H. - Transfer

Factor: Past, present and future. Annu Rev

Pharmacol Toxicol, 29: 475-516, 1989.

10. Fudenberg H.H., Smith C.L. - Immunomodu-

lation and immunotherapy: an overview of

biologic and synthetic agents and their

effects on the human immune system. EOS

Riv. Immunol Immunopharmacol, 1: 3-11,

1981.

11. Fudenberg H.H., Wilson G.B. et al - Dialy-

zable Leucocyte Extracts (Transfer Factor): A

review of clinical results and immunological

methods for donor selection, evaluation of

activities and patient monitoring. In:

Thymus, Thymic Hormones and T

Lymphocytes. Eds: Aiuti F, Wigzell H. Proc

Serono Symp, Academic Press, London,

38: 391-421, 1980.

12. Fudenberg H.H., Wilson G.B., Tsang K.Y.

- Evaluation of transfer cator potency and

prediction of clinical response. In: Immuno-

modulation: New Frontiers and Advances.

Eds: Fudenberg H.H., Whitten H., Ambro-

gi F. Plenum Press, New York, pp.115-

130, 1984.

13. Fusjisawa T., Yamaguchi Y., Kimura H. et al

- Adjuvant immunotherapy of primary resec-

ted lung cancer with transfer factor. Cancer,

54, 663-669, 1984.

14. Gonzalez R.L., Wong P., Spitler L.E. - Adju-

vant immunotherapy with Transfer Factor in

patients with melanoma metastatic to lung.

Cancer, 45, 57-63, 1980.

15. Greiner J.W., Fisher P.B., Pestka S., Schlom

J.: Differential effects of recombinant human

leukocyte interferon on cell surface antigen

expression. Cancer Res, 46, 4984-4990,

1986.

16. Huo B. - Clinical application of Transfer

Factor in China.ibidem pp. 451-459.

17. Jones J.F., Minnich L.L., Jeter W.-S., Pritchett,

Fulginiti V.A., Wedgwood R.J. - treatment of

childood combined Epstein-Barr virus/cyto-

GUNA-TF

Literature references

megalovirus infection with oral bovine trans-

fer factor. Lancet 2: 122-124, 1981.

18. Jones J.F., Pizza G., De Vinci C. - Infectious

mononucleosis: immunotherapy with EBV-

specific Transfer Factor? J Exp Pathol, 3(4),

399-406, 1987.

19. Kirkpatrick C.H. - Transfer Factor - Perspective

in human and veterinary medicine. J Exp

Pathol, vol 3(4), 383-398, 1987.

20. Lawrence H.S. - Proc. Soc. Exp. Biol Med

71, 516, 1949.

21. Malzac J. - Applicazioni terapeutiche dei

Transfer-factors nella prassi clinica quotidiana:

prime esperienze e risultati clinici - La Medici-

na Biologica 1997/2 Supplemento, pagg.

50-54.

22. Malzac J. - Transfer Factor, specifica attivazio-

ne della memoria del linfocita - La Medicina

Biologica 1996/2 Supplemento, pagg. 46-

50.

23. Mazzella G., Ronchi M., Villanova N.,

Mohamed A.A., Pizza G., De Vinci C., Viza

D., Roda E., Barbara L. - Treatment of chronic

B virus hepatitis with specific Transfer Factor. J

Exp Pathol, 3, 421-423, 1987.

24. Meduri R., Campos E., Scorolli L., De Vinci

C., Pizza G., Vizà D. - Efficacia del Transfer

Factor nel trattamento di pazienti con infezio-

ni erpetiche oculari ricorrenti. In: “Biotherapy”

9/1996.

25. Neequaye J., Viza D., Pizza G., Levine P.H.,

De Vinci C. et al - Specific Transfer Factor

with activity against Epstein-Barr virus reduces

late relapse in endemic Burkitt's lymphoma.

Anticancer Res, 10,: 1183-1188, 1990.

26. Nkrumah F.K., Pizza G., Neequaye J., Viza

D., De Vinci C., Levine P.H. - Transfer Factor

in prevention of Burkitt's Lymphoma relapses.

J Exp Pathol, 3, 463-469, 1987.

27. Orlandini A. - Il Transfer Factor: la proteina

responsabile del trasferimento della reattività

cellulo mediata verso antigeni specifici - La

Medicina Biologica 1996/2; pagg. 37-42.

28. Paddock G.V., Wilson G.B., Lin F.K.,

O'Leary, Fudenberg H.H. - In: Electrophoresis

'81, Eds: Allen R, Arnaud P. Edited by De

Gruyter, NY, pp. 479-486, 1981.

29. Pizza G., Viza D., Ablashi D.V., Faggioni A.,

Armstrong G., Levine P.H., De Vinci C., Inno-

centi R. - Transfer of reactivity with in vitro pro-

duced Transfer Factor in Rhesus and Owl

monkeys. Lymphokine Res, 4, 351-357,

1985.

30. Pross HF, Baines M. - Studies of human natu-

ral killer cells. I. In vivo parameters affecting

normal cytotoxic function. Int J Cancer, 29,

383-390, 1982.

31. Roda E., Pizza G., Viza D., Mastroroberto L.,

De Vinci C., Barbara L.: Transfer Factor for

the treatment of HBsAg positive chronic acti-

ve hepatitis. Proc Soc Biol Med (Usa), 178,

405-410, 1985.

32. Sasakawa S., Takenouchi K., Masumoto C.,

Mura T., Saito S et al: Clinical trials of dialy-

zable leukocyte extract (RCTF-I) in Japan. In:

Leukocyte Dialyzates and Transfer Factor, Eds

Mayer V, Borvak, pp.141-145. Inst Virol, Slo-

vak Acad Sci, 1987.

33. Schwartz R.S., Jeter W.S. - Oral-administra-

tion of human dializable transfer factor in a

patient with psoriasis. Arch Dermatol, 117:

3-4, 1981.

34. Viza D., Rosenfeld F., Phillips J., Vich J.M.,

Denis, Bonissent J.F., Dogbe K. - Specific

bovine transfer factor for the treatment of her-

pes infections. In: Immunobiology of Transfer

Factor, Kirkpatrick CH, Burger DR, Lawrence

HS Eds, Ac Press, NY, 245-259, 1983.

35. Viza D. - Transfer Factor: un immunomodu-

latore nella lotta contro le malattie infettive -

La Medicina Biologica 2000/4, pagg.

31-37.

36. Viza D., Orlandini A. - Il Transfer Factor spe-

cifico (TF 11) nel trattamento delle affezioni

muco-cutanee da Papillomavirus (HPV) - La

Medicina Biologica 1999/3, pagg. 11-

15.

37. Whyte R.I., Schork A., Sloan H., Orringer

M.B., Kirsh M.M. - Adjuvant treatment

using for bronchogenic carcinoma: long-

term follow-up. Ann Thorac Surg 53, 391-

6, 1992.

38. Wilson G.B., Fudenberg H.H. - Is contro-

versy about “transfer factor therapy” near

the end? Immunol Today. 4: 157-161,

1983.

39. Wilson G.B., Jonsson H.T., Halushka P.V.,

Garner B.P., Berkaw M.N. - Contribution of

prostaglandins to the biological activity of

Dyalizable Leukocytes Extracts containing

Transfer Factor. Ibidem, pp.137-150.

40. Wilson G.B., Metcalf J.F. jr., Fudenberg

H.H. - Treatment of Mycobacterium fortui-

tum pulmonary infection with Transfer Fac-

tor: New methodology for evaluating TF

potency and predicting clinical response.

Clin Immunol Immunopathol, 23, 478-

491, 1982.

41. Wilson G.B., Paddock G.V., Fudenberg

H.H.: Bovine “Transfer Factor”: an oligori-

bonucleopeptide wich initiates antigen-spe-

cific lymphocyte responsiveness. Thymus,

4: 335-350, 1982.

42. Wilson G.B., Paddock G.V., Fudenberg

H.H.: Effect of dialyzable leukocyte extracts

with transfer factor activity on leukocytes

migration in vitro. V. Antigen-specific

lymphocyte responsiveness can be iniated

by two structurally distinct polyribonucleoti-

des. Thymus 2: 257-276, 1981.

Literature references

Contact UsFor USA customersGUNA Incorporated1520 Tramway Blvd. NE, STE, 150 Albuquerque, New Mexico 87112, USA1-888-GUNA-TEL (486-2835)1-888-GUNA-FAX (486-2329)Contact your Medical Sales Consultant directly at: 505-217-3977 or fax to 505-217-3996Please give us your opinion and feedback by emailing us at info@gunainc.com

For all other countries outside the United StatesPlease email us at export@guna.it

GUNA S.p.a.Via Palmanova, 71 – 20132 MILANOTel. 02.28018.1 – Fax 02.2822234Internet: www.guna.it – e-mail: info@guna.it

DO

CU

ME

NTA

ZIO

NE

SC

IEN

TIF

ICA

RIS

ER

VAT

A A

LLA

CLA

SS

E M

ED

ICA

Cod

.:7G

N04

6S

tam

pa:1

2/20

05

GU

NA

-TF